Compare TRMB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMB | MDGL |
|---|---|---|
| Founded | 1978 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.1B |
| IPO Year | 1996 | 2005 |
| Metric | TRMB | MDGL |
|---|---|---|
| Price | $50.60 | $525.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $93.50 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 3.2M | 275.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $3,798,700,000.00 | $180,133,000.00 |
| Revenue This Year | $9.92 | $58.39 |
| Revenue Next Year | $8.04 | $48.55 |
| P/E Ratio | $119.48 | ★ N/A |
| Revenue Growth | ★ 3.33 | N/A |
| 52 Week Low | $47.92 | $284.02 |
| 52 Week High | $87.50 | $615.00 |
| Indicator | TRMB | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 60.87 |
| Support Level | $47.92 | $498.59 |
| Resistance Level | $69.89 | $540.72 |
| Average True Range (ATR) | 1.68 | 17.70 |
| MACD | 0.26 | 4.64 |
| Stochastic Oscillator | 38.91 | 90.19 |
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.